Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Stopped Study did not meet Phase Ib primary objective to establish the maximum tolerated dose/recommended dose for Phase II

Conditions

• Inoperable Locally Advanced Breast Cancer
• Metastatic Breast Cancer (MBC)

Interventions

• DRUG: BEZ235
• DRUG: Paclitaxel

Sponsor

Novartis Pharmaceuticals